

**S1 Table.** Univariable and multivariable Cox regression analysis for PFS in all patients (n=100)

Variable	No. of patients	Univariable		Multivariable	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age <sup>a)</sup> (yr)					
< 65	55	1		1	
≥ 65	45	0.93 (0.61-1.42)	0.735	0.87 (0.55-1.38)	0.562
Sex					
Male	63	1		1	
Female	37	0.91 (0.59-1.40)	0.654	0.42 (0.13-1.44)	0.168
Smoking status					
Never smoker	37	1		1	
Former smoker	63	0.98 (0.63-1.52)	0.926	0.31 (0.09-1.05)	0.060
Histologic type					
Others <sup>b)</sup>	74	1		1	
Adenocarcinoma	15	1.43 (0.71-2.87)	0.321	0.84 (0.34-2.12)	0.715
Squamous cell carcinoma	11	3.07 (1.33-7.11)	0.009	1.83 (0.62-5.38)	0.275
<i>EGFR</i> mutation status					
Negative	85	1.53 (0.87-2.69)	0.140	-	-
Positive	15	-	-	-	-
Type of ICI					
Monotherapy	88	1		-	-
Combination <sup>c)</sup>	12	1.02 (0.55-1.89)	0.952	-	-
Prior treatment line					
1	19	1		-	-
≥2	81	1.36 (0.80-2.31)	0.258	-	-
PD-L1 expression					
<1%	42	1		1	
1-49%	34	1.15 (0.72-1.84)	0.560	1.17 (0.73-1.88)	0.515
≥50%	24	0.53 (0.30-0.92)	0.024	0.46 (0.23-0.96)	0.037
<i>TP53</i> mutation status					
Negative	41	1		-	-
Positive	59	0.98 (0.65-1.49)	0.931	-	-

CI, confidence interval; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; HR, hazard ratio; PD-L1, programmed death-ligand 1; PFS, progression-free survival. <sup>a)</sup>At ICI initiation, <sup>b)</sup>This includes poorly differentiated (n=6), sarcomatoid carcinoma (n=4), and large-cell neuroendocrine type (n=1), <sup>c)</sup>ICI treatment combined with cytotoxic chemotherapy.